Inicio
Explorar
nav.journalClub
Tendencias
Más
synapse
⌘+K
Idioma
Español
Español
April 8, 2026
Urinary Leukotriene E4 as a Biomarker of Disease Burden in Aspirin‐Exacerbated Respiratory Disease: A Retrospective Cohort Study
AA
Alaa Alhalabi
Jacksonville College
IE
Isaac Elijah
BV
Bastien A. Valencia
Ver todo
Puntos clave
To evaluate the role of urinary leukotriene E4 as a biomarker in assessing disease burden in aspirin-exacerbated respiratory disease.
Conducted a retrospective cohort study
Analyzed urinary leukotriene E4 levels in patients with aspirin-exacerbated respiratory disease
Compared disease burden measures with leukotriene E4 levels
Urinary leukotriene E4 levels correlated with higher disease burden
Patients with elevated leukotriene E4 exhibited more severe respiratory symptoms
Findings suggest urinary leukotriene E4 can serve as a reliable biomarker for monitoring disease severity
Resumen
The authors declare no conflicts of interest.
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Mark Helpful
Me gusta
Save
Guardar
Relay
Compartir
Cite This Study
Copy
Alhalabi et al. (Mon,) studied this question.
synapsesocial.com/papers/69d5f03374eaea4b11a79b83
https://doi.org/https://doi.org/10.1002/alr.70157
Urinary Leukotriene E4 as a Biomarker of Disease Burden in Aspirin‐Exacerbated Respiratory Disease: A Retrospective Cohort Study | Synapse